These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29878660)

  • 41. Emerging genetic and pharmacologic therapies for controlling hemostasis: beyond recombinant clotting factors.
    Monahan PE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():33-40. PubMed ID: 26637698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The leak stops here: platelets as delivery vehicles for coagulation factors.
    High KA
    J Clin Invest; 2006 Jul; 116(7):1840-2. PubMed ID: 16823486
    [TBL] [Abstract][Full Text] [Related]  

  • 43. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system.
    Yakura Y; Ishihara C; Kurosaki H; Kazuki Y; Komatsu N; Okada Y; Doi T; Takeya H; Oshimura M
    Biochem Biophys Res Commun; 2013 Feb; 431(2):336-41. PubMed ID: 23291180
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Combined coagulation factor VIII and factor IX deficiency (CDF8F9) in a patient from Lithuania.
    Ivaškevičius V; Pezeshkpoor B; Biswas A; Goldmann G; Horneff S; Gimbutyte M; Malciute L; Jurgutis R; Oldenburg J
    Hamostaseologie; 2016 Nov; 36(Suppl. 2):S29-S33. PubMed ID: 27824213
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Advances in Gene Therapy for Hemophilia.
    Nathwani AC; Davidoff AM; Tuddenham EGD
    Hum Gene Ther; 2017 Nov; 28(11):1004-1012. PubMed ID: 28835123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reply to: Gene therapy to cure haemophilia: Is robust scientific inquiry the missing factor?
    Winburn I; Schulz M; LaRosa G; Azzouz M
    Haemophilia; 2021 Sep; 27(5):e628-e629. PubMed ID: 34156740
    [No Abstract]   [Full Text] [Related]  

  • 47. Preclinical and clinical advances in transposon-based gene therapy.
    Tipanee J; Chai YC; VandenDriessche T; Chuah MK
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 29089466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Gene therapy: a 2001 perspective.
    High KA
    Haemophilia; 2001 Jan; 7 Suppl 1():23-7. PubMed ID: 11240615
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides.
    Hodges BL; Taylor KM; Joseph MF; Bourgeois SA; Scheule RK
    Mol Ther; 2004 Aug; 10(2):269-78. PubMed ID: 15294174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Molecular genetics of hemophilia A].
    De Brasi CD; Slavutsky IR; Larripa IB
    Medicina (B Aires); 1996; 56(5 Pt 1):509-17. PubMed ID: 9239887
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.
    McCORMACK WM; Seiler MP; Bertin TK; Ubhayakar K; Palmer DJ; Ng P; Nichols TC; Lee B
    J Thromb Haemost; 2006 Jun; 4(6):1218-1225. PubMed ID: 16706963
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospects for gene therapy of haemophilia.
    Nathwani AC; Davidoff AM; Tuddenham EG
    Haemophilia; 2004 Jul; 10(4):309-18. PubMed ID: 15230943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimized human factor IX expression cassettes for hepatic-directed gene therapy of hemophilia B.
    Zhang R; Wang Q; Zhang L; Chen S
    Front Med; 2015 Mar; 9(1):90-9. PubMed ID: 25663062
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gene therapy ethics and haemophilia: an inevitable therapeutic future?
    Dimichele D; Miller FG; Fins JJ
    Haemophilia; 2003 Mar; 9(2):145-52. PubMed ID: 12614364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic engineering for haemophilia A.
    Gan SU; Kon OL; Calne RY
    Expert Opin Biol Ther; 2006 Oct; 6(10):1023-30. PubMed ID: 16989584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adeno-associated virus (AAV) vectors in cancer gene therapy.
    Santiago-Ortiz JL; Schaffer DV
    J Control Release; 2016 Oct; 240():287-301. PubMed ID: 26796040
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Haemophilia, state of the art and new therapeutic opportunities, a regulatory perspective.
    Tomeo F; Mariz S; Brunetta AL; Stoyanova-Beninska V; Penttila K; Magrelli A
    Br J Clin Pharmacol; 2021 Nov; 87(11):4183-4196. PubMed ID: 33772837
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gene therapy for haemophilia: a long and winding road.
    High KA
    J Thromb Haemost; 2011 Jul; 9 Suppl 1():2-11. PubMed ID: 21781236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet-delivered therapeutics.
    Lyde R; Sabatino D; Sullivan SK; Poncz M
    J Thromb Haemost; 2015 Jun; 13 Suppl 1():S143-50. PubMed ID: 26149015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.